DocWire News spoke with Raj Chakraborty, MD, assistant professor of medicine at Columbia University Irving Medical Center, Division of Hematology/Oncology, on the benefits of antibody drug conjugates (ADC) for multiple myeloma.

This is the fourth in a four part conversation on treatments for multiple myeloma with Dr. Chakraborty. Watch part one, on recent clinical trials for newly-diagnosed disease, part two, on the challenges of the paradigm shift to quadruplet therapy, and part three, on bispecific T-cell engagers (BiTEs).